newsfilter
← Latest News
Business Wire·

La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced its intention to offer and sell $100,000,000 of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. All of the shares to be sold in the proposed public offering are being offered by La Jolla.